June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Comparison of visual function in structurally defined sub-phenotypes of intermediate AMD: A MACUSTAR study report
Author Affiliations & Notes
  • Hannah M P Dunbar
    UCL Institute of Ophthalmology, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Marlene Sassmannshausen
    Department of Ophthalmology, University of Bonn, Germany
  • Charlotte Behning
    Universitat Bonn Institut fur Medizinische Biometrie Informatik und Epidemiologie, Bonn, Germany
  • Sarah Thiele
    Department of Ophthalmology, University of Bonn, Germany
  • Alison Binns
    City University of London, London, London, United Kingdom
  • Bethany Elora Higgins
    City University of London, London, London, United Kingdom
  • Jan Henrik Terheyden
    Department of Ophthalmology, University of Bonn, Germany
  • Adnan Tufail
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
    UCL Institute of Ophthalmology, United Kingdom
  • Sergio Leal
    Bayer Pharmaceuticals, Germany
  • Nadia Zakaria
    Translational Medicine, Novartis Institute for Biomedical Research, Massachusetts, United States
  • Frank G Holz
    Department of Ophthalmology, University of Bonn, Germany
  • Matthias C Schmid
    Universitat Bonn Institut fur Medizinische Biometrie Informatik und Epidemiologie, Bonn, Germany
  • Robert P Finger
    Department of Ophthalmology, University of Bonn, Germany
  • David P. Crabb
    City University of London, London, London, United Kingdom
  • Steffen Schmitz-Valckenberg
    Department of Ophthalmology, University of Bonn, Germany
  • Ulrich F O Luhmann
    Roche Pharmaceutical Research and Early Development, Switzerland
  • Footnotes
    Commercial Relationships   Hannah Dunbar Boeringer Ingelheim, Code C (Consultant/Contractor); Marlene Sassmannshausen Heidelberg Engineering, Code F (Financial Support), Centrevue, Code F (Financial Support), Carl Zeiss MedicTech, Code F (Financial Support); Charlotte Behning None; Sarah Thiele Heidelberg Engineering, Optos, Zeiss, CenterVue, Code F (Financial Support), Heidelberg Engineering, Novartis, Bayer, Allergan, Code R (Recipient); Alison Binns None; Bethany Higgins None; Jan Terheyden Heidelberg Engineering, Code F (Financial Support), Optos, Code F (Financial Support), Carl Zeiss MedicTec, Code F (Financial Support), CenterVue, Code F (Financial Support), Okko health, Code R (Recipient); Adnan Tufail None; Sergio Leal Bayer, Code E (Employment); Nadia Zakaria Novartis Institute for Biomedical Research, Code E (Employment); Frank Holz Acucela, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, Roche/Genentech, Geuder, Graybug, Gyroscope, Heidelberg Engineering, IvericBio, Kanghong, LinBioscience, Novartis, Oxurion, Pixeum Vision, Stealth BioTherapeutics, Zeiss, Code C (Consultant/Contractor), Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CentreVue, Ellex, Roche/Genentech, Geuder, Heidelberg Engineering, IvericBio, Kanghong, NightStarX, Novartis, Optos, Pixeum Vision, Zeiss, Code F (Financial Support), GRADE Reading Center, Code O (Owner); Matthias Schmid None; Robert Finger Bayer, Novartis, Roche/Genentech, Allergan, Alimera, Böhringer-Ingelheim, Chiesi, Santhera, Ellex, ProQR, Opthea, Inositec , Code C (Consultant/Contractor), Novartis, Zeiss, Heidelberg Engineering, CentreVue, Biogen, Code F (Financial Support); David Crabb Santen, Allergan/Abbvie, Apellis, Code F (Financial Support), Santen, Allergan/Abbvie, Apellis, THEA, Centervue, Roche, Code R (Recipient); Steffen Schmitz-Valckenberg AlphaRET, Apellis, Bioeq, Katairo, Kubota Vision, Novartis, Oxurion, Pixium, Roche, SparingVision, Code C (Consultant/Contractor), Bayer, Carl Zeiss MediTech, Heidelberg Engineering, Novartis, Roche , Code F (Financial Support), STZ GRADE Reading Center, Code O (Owner), Apellis, Heidelberg Engineering, Code R (Recipient); Ulrich Luhmann F. Hoffmann-La Roche Ltd , Code E (Employment)
  • Footnotes
    Support  Innovative Medicines Initiative 2 Joint Undertaking 439 under grant agreement No 116076. This Joint Undertaking receives support from the 440 European Union’s Horizon 2020 research and innovation programme and EFPIA.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 880. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hannah M P Dunbar, Marlene Sassmannshausen, Charlotte Behning, Sarah Thiele, Alison Binns, Bethany Elora Higgins, Jan Henrik Terheyden, Adnan Tufail, Sergio Leal, Nadia Zakaria, Frank G Holz, Matthias C Schmid, Robert P Finger, David P. Crabb, Steffen Schmitz-Valckenberg, Ulrich F O Luhmann; Comparison of visual function in structurally defined sub-phenotypes of intermediate AMD: A MACUSTAR study report. Invest. Ophthalmol. Vis. Sci. 2022;63(7):880.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate whether reclassifying eyes with intermediate (i)AMD by additional imaging-based biomarkers identifies sub-phenotypes of iAMD with reduced visual function (VF).

Methods : People with no AMD and Beckman defined iAMD in the MACUSTAR study performed Best Corrected Visual Acuity (BCVA), Low Luminance Visual Acuity (LLVA), Moorfields Acuity Test (MAT), Pelli Robson Contrast Sensitivity (CS), International Reading Speed Test (IReST), Mesopic (MesAT) and Scotopic (ScoAT) average thresholds (S-MAIA microperimetry) and AdaptDx Rod Intercept Time (RIT), followed by multimodal imaging (colour fundus and confocal infrared photography, fundus autofluorescence and spectral domain optical coherence tomography). Images were graded by a central reading centre for presence of the following features: pigmentary abnormalities (PA), reticular pseudodrusen (RPD), incomplete and complete retinal pigment epithelium and outer retinal atrophy (iRORA and cRORA). Pairwise complete VF data were compared across three structurally defined groups; no AMD, iAMD feature absent(-) and iAMD feature present(+) using nonparametric Kruskal-Wallis, followed by pairwise Wilcoxon tests. Being a signal seeking exploratory analysis, multiple testing correction was not applied.

Results : 224 people (n=56 no AMD [33F; mean age 68 yrs]; n=168 iAMD [106F; 71 yrs]) were included in this analysis. Of those with iAMD, 96(57%) had PA, 37(22%) had RPD, 18(11%) had iRORA and 7(4%) had cRORA. With the exception of IReST, those with iAMD and absent structural features had worse median VF than those with no AMD on all measures (p<0.01). LLVA, CS, MesAT, ScoAT and RIT were worse in those with iAMD+RPD compared to iAMD–RPD (p<0.04). LLVA, CS, MAT, MesAT and ScoAT were worse in those with iAMD+cRORA compared to iAMD–cRORA (p<0.05). CS was worse in those with iAMD+PA compared to iAMD–PA (p=0.01). There were no median differences between presence or absence of iRORA in any VF measure.

Conclusions : Though ascribed the same AMD disease stage, eyes with iAMD+RPD and iAMD+cRORA had poorer low luminance and contrast vision than other iAMD eyes. As the number of eyes with observed structural features is small, we aim to confirm our findings in a large longitudinal cohort and examine whether additional structural or functional features should be accounted for in AMD disease classification or used as entry criteria in treatment trials.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×